Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Schiffer JT, Wald A, Selke S, Corey L, Magaret A.

J Infect Dis. 2011 Aug 15;204(4):554-61. doi: 10.1093/infdis/jir314.

2.

Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.

Schiffer JT, Magaret A, Selke S, Corey L, Wald A.

J Antimicrob Chemother. 2011 Nov;66(11):2593-600. doi: 10.1093/jac/dkr346. Epub 2011 Aug 24.

3.

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A.

JAMA. 2011 Apr 13;305(14):1441-9. doi: 10.1001/jama.2011.420.

4.

Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.

Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, Magaret A, Koelle DM, Wald A, Corey L.

J Virol. 2014 May;88(9):4921-31. doi: 10.1128/JVI.03285-13. Epub 2014 Feb 19.

5.

Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L.

N Engl J Med. 2000 Mar 23;342(12):844-50.

6.

Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. doi: 10.1073/pnas.1006614107. Epub 2010 Oct 18.

7.

Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling.

Crespi CM, Cumberland WG, Wald A, Corey L, Blower S.

Sex Transm Infect. 2007 Aug;83(5):359-64. Epub 2007 May 2.

8.

Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.

Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang ML, Warren T, Casper C, Corey L, Wald A.

J Infect Dis. 2011 Jan 15;203(2):180-7. doi: 10.1093/infdis/jiq035. Epub 2010 Dec 9.

9.

Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.

Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L.

J Infect Dis. 2008 Oct 15;198(8):1141-9. doi: 10.1086/591913.

10.

Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L.

Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.

11.

Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults.

Mark KE, Wald A, Magaret AS, Selke S, Kuntz S, Huang ML, Corey L.

J Acquir Immune Defic Syndr. 2010 Aug;54(5):482-8. doi: 10.1097/QAI.0b013e3181d91322.

12.

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Schiffer JT, Swan DA, Corey L, Wald A.

Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9. doi: 10.1128/AAC.01114-13. Epub 2013 Sep 9.

13.

Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.

Dhankani V, Kutz JN, Schiffer JT.

PLoS Comput Biol. 2014 Nov 6;10(11):e1003922. doi: 10.1371/journal.pcbi.1003922. eCollection 2014 Nov.

14.

One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.

Bavaro JB, Drolette L, Koelle DM, Almekinder J, Warren T, Tyring S, Wald A.

Sex Transm Dis. 2008 Apr;35(4):383-6. doi: 10.1097/OLQ.0b013e31815e4190.

PMID:
18362859
15.

Genital shedding of herpes simplex virus among men.

Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L.

J Infect Dis. 2002 Oct 15;186 Suppl 1:S34-9.

16.

Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.

Tata S, Johnston C, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Infect Dis. 2010 Feb 15;201(4):499-504. doi: 10.1086/650302.

17.

Virologic characteristics of subclinical and symptomatic genital herpes infections.

Wald A, Zeh J, Selke S, Ashley RL, Corey L.

N Engl J Med. 1995 Sep 21;333(12):770-5.

18.

Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding.

Schiffer JT, Mayer BT, Fong Y, Swan DA, Wald A.

J R Soc Interface. 2014 Mar 26;11(95):20140160. doi: 10.1098/rsif.2014.0160. Print 2014 Jun 6.

19.

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.

Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J.

J Clin Invest. 1997 Mar 1;99(5):1092-7.

20.

Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.

Kim HN, Meier A, Huang ML, Kuntz S, Selke S, Celum C, Corey L, Wald A.

J Infect Dis. 2006 Aug 15;194(4):420-7. Epub 2006 Jul 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk